Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BKD Brookdale Senior Living	$7.92 +2.3%	$6.78	$4.45 ▼ $8.12	$1.85B	0.83	2.61 million shs	3.36 million shs
CHRS Coherus Oncology	$0.88 +1.5%	$0.81	$0.66 ▼ $2.43	$102.02M	0.86	2.66 million shs	1.68 million shs
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
ORTX Orchard Therapeutics	$16.70	$16.59	$4.24 ▼ $16.72	$380.09M	0.55	157,287 shs	N/A
TGTX TG Therapeutics	$37.08 -1.6%	$36.18	$16.65 ▼ $46.48	$5.89B	1.91	2.88 million shs	957,478 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BKD Brookdale Senior Living	+4.53%	+12.94%	+8.53%	+34.93%	+10.04%
CHRS Coherus Oncology	-0.12%	+8.26%	+7.70%	+3.74%	-39.36%
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
ORTX Orchard Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TGTX TG Therapeutics	-0.66%	+1.26%	-4.46%	+2.62%	+83.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BKD Brookdale Senior Living	3.0754 of 5 stars	1.2	5.0	0.0	4.9	1.8	0.0	0.6
CHRS Coherus Oncology	3.7528 of 5 stars	3.3	1.0	0.0	4.5	0.6	2.5	0.6
ENDP Endo International	0.4592 of 5 stars	0.0	0.0	0.0	3.5	1.1	1.7	0.0
ORTX Orchard Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	4.0313 of 5 stars	2.4	1.0	0.0	3.5	3.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BKD Brookdale Senior Living	2.40	Hold	$7.70	-2.72% Downside
CHRS Coherus Oncology	2.67	Moderate Buy	$4.68	432.20% Upside
ENDP Endo International	0.00	N/A	N/A	N/A
ORTX Orchard Therapeutics	0.00	N/A	N/A	N/A
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	18.12% Upside

Current Analyst Ratings Breakdown

Latest BKD, TGTX, ENDP, CHRS, and ORTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/9/2025	BKD Brookdale Senior Living	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$9.00
5/8/2025	BKD Brookdale Senior Living	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
4/29/2025	CHRS Coherus Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/24/2025	CHRS Coherus Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.05
4/16/2025	BKD Brookdale Senior Living	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $7.50

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BKD Brookdale Senior Living	$3.16B	0.59	$0.88 per share	8.95	$1.07 per share	7.40
CHRS Coherus Oncology	$272.25M	0.37	$0.30 per share	2.98	($1.14) per share	-0.77
ENDP Endo International	$2.99B	0.00	N/A	0.06	($13.60) per share	0.00
ORTX Orchard Therapeutics	$22.66M	16.77	N/A	N/A	$7.74 per share	2.16
TGTX TG Therapeutics	$329M	17.89	$0.12 per share	316.10	$1.43 per share	25.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BKD Brookdale Senior Living	-$201.93M	-$1.04	N/A	N/A	N/A	-7.52%	-79.84%	-3.33%	8/14/2025 (Estimated)
CHRS Coherus Oncology	$28.51M	-$1.13	N/A	N/A	N/A	-66.30%	N/A	-26.51%	8/6/2025 (Estimated)
ENDP Endo International	-$613.24M	-$11.07	N/A	0.00	N/A	-93.31%	-34.25%	6.72%	N/A
ORTX Orchard Therapeutics	-$150.66M	-$0.94	N/A	N/A	N/A	-333.90%	-74.94%	-33.51%	N/A
TGTX TG Therapeutics	$23.38M	$0.24	154.50	37.08	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest BKD, TGTX, ENDP, CHRS, and ORTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
5/12/2025	Q1 2025	CHRS Coherus Oncology	-$0.31	-$0.35	-$0.04	-$0.49	$59.79 million	$7.60 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	BKD Brookdale Senior Living	-$0.11	-$0.11	N/A	-$0.28	$816.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BKD Brookdale Senior Living	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
ENDP Endo International	N/A	N/A	N/A	N/A	N/A
ORTX Orchard Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BKD Brookdale Senior Living	28.85	0.82	0.82
CHRS Coherus Oncology	N/A	1.22	1.20
ENDP Endo International	N/A	1.86	1.62
ORTX Orchard Therapeutics	0.20	3.12	2.98
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BKD Brookdale Senior Living	N/A
CHRS Coherus Oncology	72.82%
ENDP Endo International	80.39%
ORTX Orchard Therapeutics	29.90%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BKD Brookdale Senior Living	1.80%
CHRS Coherus Oncology	8.08%
ENDP Endo International	1.20%
ORTX Orchard Therapeutics	2.91%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BKD Brookdale Senior Living	36,000	234.35 million	230.13 million	Optionable
CHRS Coherus Oncology	330	115.93 million	106.57 million	Optionable
ENDP Endo International	3,103	235.14 million	232.32 million	No Data
ORTX Orchard Therapeutics	166	22.76 million	22.10 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

BKD, TGTX, ENDP, CHRS, and ORTX Headlines

Recent News About These Companies

Banque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)

July 11 at 5:39 AM | marketbeat.com

TG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90

July 10 at 10:31 PM | msn.com

TG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite Rating

July 10 at 10:31 PM | msn.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

July 10 at 11:09 AM | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs Group

July 10 at 10:24 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLC

July 9 at 3:32 AM | marketbeat.com

Axsome Therapeutics Sees Relative Strength Rating Climb To 79

July 8 at 1:53 PM | msn.com

Penserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8 at 5:57 AM | marketbeat.com

Principal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8 at 4:13 AM | marketbeat.com

New York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 7, 2025 | marketbeat.com

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5, 2025 | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2, 2025 | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2, 2025 | msn.com

Cramer's Lightning Round: TG Therapeutics is a buy

June 30, 2025 | nbcnewyork.comN

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund

June 30, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Financials - Morningstar

June 28, 2025 | morningstar.comM

TG Therapeutics: Strong Execution Tempered By An Evolving Market

June 28, 2025 | seekingalpha.com

Spire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 28, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Stocks With Rising Relative Strength: CRISPR Therapeutics

June 26, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKD, TGTX, ENDP, CHRS, and ORTX Company Descriptions

Brookdale Senior Living NYSE:BKD

$7.92 +0.18 (+2.26%)

Closing price 03:58 PM Eastern

Extended Trading

$7.93 +0.01 (+0.19%)

As of 06:58 PM Eastern

Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.

Coherus Oncology NASDAQ:CHRS

$0.88 +0.01 (+1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.34%)

As of 07:23 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Orchard Therapeutics NASDAQ:ORTX

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

TG Therapeutics NASDAQ:TGTX

$37.08 -0.59 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$37.16 +0.08 (+0.22%)

As of 06:35 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time